Atacicept's Phase 3 ORIGIN Trial Final Efficacy Analysis Published in IgA Nephropathy
Start here
The New England Journal of Medicine has published online the final efficacy analysis of the phase 3 ORIGIN trial, which evaluated atacicept in patients with IgA nephropathy, a disease in which antibody deposits damage the kidneys' filtering units. Atacicept works by dampening the B-cell pathways that drive production of the offending antibodies. The publication marks the completion of the trial's pre-specified final efficacy analysis, giving clinicians and researchers peer-reviewed data on the drug's effects in this condition. The detailed results are still being reviewed, and open questions include how the findings translate into clinical practice and how atacicept compares with other emerging therapies for IgA nephropathy.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- nejm.orgAtacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis
The New England Journal of Medicine has published online the final efficacy analysis of the phase 3 ORIGIN trial of atacicept in IgA nephropathy. The full detailed results remain to be reviewed.
Heat trend for this story
Heat now 4·Peak in the comparable set 10 (Oct 22 10:00)·Change over 24h in the comparable set -51%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.